Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates

Atara Biotherapeutics (ATRA) came out with a quarterly loss of $2.93 per share versus the Zacks Consensus Estimate of a loss of$ 3.77. This compares to loss of $16.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 22.28%. A quarter ago, it was expected that this drug developer would post a loss of$ 1.25 per share when it actually produced a loss of $3.10, delivering a surprise of -148%.Over the last four quarters, the company ...